Literature DB >> 12210405

HBV subtype as a marker of the clinical course of chronic HBV infection in Japanese patients.

Takahisa Sakai1, Katsuya Shiraki, Hidekazu Inoue, Hiroshi Okano, Masatoshi Deguchi, Kazushi Sugimoto, Shigeru Ohmori, Kazumoto Murata, Hiromichi Fujioka, Koujirou Takase, Yukihiko Tameda, Takeshi Nakano.   

Abstract

Hepatitis B virus (HBV) genotype C is predominant in Japan. However, many HBV subtypes are involved in each genotype, and the clinical manifestations in the patients associated with each subtype remain unknown. Therefore, we investigated the relationship between HBV subtype and clinical aspects of chronic HBV infection. The subtype of 237 patients with chronic HBV infection, including 74 asymptomatic carriers, was determined. The subtypes of 110 HBV carriers undergoing long-term follow-up management were determined twice to detect subtypic changes. The clinical features of the patients were also studied with regard to presence or absence of subtypic change. The subtypic distribution in the 237 HBV carriers was as follows: subtype adr, 161 (68%); subtype adw, 25 (11%); subtype adwr, 12 (5%); subtype ar, 24 (10%); subtype adyr, 4 (2%); and unclassified, 8 (3%). The proportion of asymptomatic carriers in patients with subtype adw was significantly higher than those in patients with subtype adr (56% vs. 28%, P < 0.05). In addition, the proportion of HCC in patients with subtype adwr was significantly higher than those in patients with subtype adr (25% vs. 6%, P < 0.05). The prevalence of subtype adr in 74 asymptomatic carriers tended to decrease with age (82% in carriers aged < or =35 years vs 43% in those aged > or =61 years, P < 0.05). The subtypic change and the course of chronic HBV infection had no significant correlation. These results suggest that HBV subtypes are associated with the clinical course of chronic HBV infection. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210405     DOI: 10.1002/jmv.10180

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.

Authors:  Joseph J Y Sung; Stephen K W Tsui; Chi-Hang Tse; Eddie Y T Ng; Kwong-Sak Leung; Kin-Hong Lee; Tony S K Mok; Angeline Bartholomeusz; Thomas C C Au; Kelvin K F Tsoi; Stephen Locarnini; Henry L Y Chan
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

Review 2.  Hepatitis B virus genotypes: global distribution and clinical importance.

Authors:  Mustafa Sunbul
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

3.  Hepatitis B virus genotypes and precore and core mutants in UAE patients.

Authors:  Mubarak Alfaresi; Abida Elkoush; Hajer Alshehhi; Azza Alzaabi; Adeel Islam
Journal:  Virol J       Date:  2010-07-15       Impact factor: 4.099

4.  Prevalence and genotypes of hepatitis B virus infection in patients underwent coronary angiography and coronary artery bypass grafting in mazandaran heart center, sari, iran.

Authors:  Tahoora Mousavi; Shervin Ziabakhsh-Tabary; Ali Ghaemiyan; Mohammad Reza Haghshenas
Journal:  Med Arch       Date:  2014-10-15

5.  Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil.

Authors:  Priscila A Tonetto; Neiva S L Gonçales; Viviane C Fais; Aline G Vigani; Eduardo S L Gonçales; Adriana Feltrin; Fernando L Gonçales
Journal:  BMC Infect Dis       Date:  2009-09-08       Impact factor: 3.090

6.  Evaluation of PCR-RFLP in the Pre-S Region as Molecular Method for Hepatitis B Virus Genotyping.

Authors:  Rim Ouneissa; Olfa Bahri; Ahlem Ben Yahia; Henda Touzi; Mohamed Msaddak Azouz; Nabyl Ben Mami; Henda Triki
Journal:  Hepat Mon       Date:  2013-10-15       Impact factor: 0.660

7.  Hepatitis B Virus Genotypes Distribution with HBsAg Positive in the North of Iran (Mazandaran) During 2011-2014.

Authors:  Tahoora Mousavi; Mohammad Reza Haghshenas; Alireza Rafiei; Reza Alizadeh Navaei; Zahra Hosseini Khah
Journal:  Med Arch       Date:  2014-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.